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Abstract
M u t a t e dt y r o s i n ek i n a s e sa r ea s s o c i a t e dw i t han u m b e ro f different haematological malignancies including
myeloproliferative disorders, lymphoma and acute myeloid leukaemia. The potential commonalities in the action of six
of these leukemogenic proteins on nuclear proteins were investigated using systematic proteomic analysis. The effects on
over 3600 nuclear proteins and 1500 phosphopeptide sites were relatively quantified in seven isogenic cell lines. The effects
of the kinases were diverse although some commonalities were found. Comparison of the nuclear proteomic data with
transcriptome data and cytoplasmic proteomic data indicated that the major changes are due to post-translational
mechanisms rather than changes in mRNA or protein distribution. Analysis of the promoter regions of genes whose protein
levels changed in response to the kinases showed the most common binding site found was that for NFkB whilst other sites
such as those for the glucocorticoid receptor were also found. Glucocorticoid receptor levels and phosphorylation were
decreased by all 6 PTKs. Whilst Glucocorticoid receptor action can potentiate NFkB action those proteins where genes have
NFkB binding sites were in often regulated post-translationally. However all 6 PTKs showed evidence of NFkB pathway
modulation via activation via altered IkB and NFKB levels. Validation of a common change was also undertaken with PMS2, a
DNA mismatch repair protein. PMS2 nuclear levels were decreased in response to the expression of all 6 kinases, with no
concomitant change in mRNA level or cytosolic protein level. Response to thioguanine, that requires the mismatch repair
pathway, was modulated by all 6 oncogenic kinases. In summary common targets for 6 oncogenic PTKs have been found
that are regulated by post-translational mechanisms. They represent potential new avenues for therapies but also
demonstrate the post-translational regulation is a key target of leukaemogenic kinases.
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Introduction
The hematopoietic system can become dysfunctional via various
distinct molecular pathologies. For example, the protein tyrosine
kinase oncoproteins (PTKs) associated with a number of different
leukaemias and preleukaemias have been identified as critical in
the molecular pathology of these diseases. They can result from
point mutations, reciprocal chromosomal translocations and
internal tandem duplication; thus in Anaplastic Large Cell
Lymphoma (ALCL) the t(2:5) translocation leads to the formation
of the NPM/ALK gene which encodes a lymphoma specific
NPM/ALK protein with intrinsic and disregulated PTK activity
[1]. A point mutation in the Kit PTK (D816V) is associated with
transformation in mast cell leukaemia [2] and in the myelopro-
liferative disorders the t(9;22) translocation found within Chronic
Myeloid Leukaemia (CML) leads to the production of the BCR/
ABL oncogenic PTK [3]. Similarly, Fip1L/PDGFRa PTK is
associated with the pathogenesis of about 50% of patients with the
hypereosinophilic syndrome [4]. TEL/PDGFRb PTK is associ-
ated with Chronic Myelomonocytic Leukaemia and is the product
of a t(9;12) chromosomal translocation [5]. The internal tandem
duplication found in Flt3 PTK (Flt3ITD) has been associated with
over 20–30% of acute myeloid leukaemia (AML) cases, the Flt3
gaining dis-regulated kinase activity resultant from this insertional
mutagenic event [6]. Thus oncogenic PTKs are associated with
many hematopoietic malignancies. A key question is therefore,
whether these kinases share a common mode of action? Certainly
there is some evidence for common activation of canonical
pathways such as the Raf/Erk cellular signalling pathway [7].
A key feature of the leukaemias and lymphomas is their
progressive nature. The potential reasons for this are numerous.
Expression of oncogenic PTKs such as BCR/ABL have been
associated with increased genomic instability [8], possibly via
increased expression of DNA polymerase b [9]. This may be
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increase the rate of DNA double strand breaks. This attritional
rate of DNA modification may then eventually lead to production
of clones that have acquired survival/proliferation advantage.
Alternatively, post-translational modification of specific proteins
may contribute to common pathways for disease progression. The
elegant work of Skorski and colleagues has implicated the
Nijmegen Break Syndrome protein (Nbs1, involved in DNA
repair) as a downstream target for several of the oncogenic PTKs
described above [11]. This has been suggested as a mechanism for
increased mutation rates. In other words specific changes in the
proteome may contribute to disregulation leading to the progres-
sive nature of leukaemia and lymphoma.
Whilst targeted therapies such as the paradigmatic use of
imatinib in treatment of CML has altered the landscape in
oncology research, the treatment does not eradicate the disease,
resistance can develop and the CML stem cell persists [12]. Thus
finding novel and common targets in leukaemias and lymphomas
may improve treatment strategies.
Methods of finding such aberrations using high throughput,
objective screens are now available. In an attempt to identify
common downstream targets we have previously described a
systematic analysis of a range of leukaemogenic kinases on the
whole cell proteome of Ba/F3 cells. Ba/F3 cells were chosen
because of their widespread usage in studies on leukemogenesis.
Leukaemia generally progresses as cells acquire further mutations
within the nucleus due to aberrant signalling cascades. We have
shown primitive hematopoietic and embryonic cells alter their
proteome with no concomitant change in mRNA [13]. Finding
changes in lower abundance nuclear proteins therefore requires
subcellular fractionation and proteomic methods. We have
analysed the nuclear proteome and phosphoproteome of Ba/F3
cells expressing 6 leukaemogenic PTKs. We demonstrate the
importance of post-translational regulation and common targets in
glucocorticoid receptor and PMS2 protein expression.
Results
Workflow for Relative Analysis of PTK Effects
We have previously described the generation and characterisa-
tion of Ba/F3 cells expressing six distinct leukaemia/lymphoma
related oncogenic protein tyrosine kinases namely BCR/ABL,
TEL/PDGFRb, Fip1L/PDGFRa, KIT D816V, NPM/ALK or
FLT3ITD [14]. Each oncogenically-transfected cell line was
shown to be independent of Interleukin 3 (IL-3 is normally
required for survival and proliferation of Ba/F3 cells) for growth
and have the same growth rate as control (MSCV Ba/F3) cells
cultured in IL-3 [14]. In depth analysis of the proteome and
phosphoproteome within the nucleus has now been performed
using the study design in Figure 1a to assess effectors potentially
modulating nuclear function. Subcellular fractionation offered the
benefit of multichannel quantification on lower abundance
proteins due to decreased analyte complexity.
The quality of the quantitative data required for such a study
was ensured by running the experiment outlined in figure 1a three
times with biological replicates in extended liquid chromatogra-
phy/MS analyses. The control cells were present in duplicate in
each of the three experiments allowing us to validate the quality of
data obtained from 8 channel iTRAQ isobaric tagging in terms of
replication and fold change in protein level [14].
Ten million cells yielded 620 mg +/224 mg of protein (mean+/
2sem) with an average nuclear to cytoplasmic ratio of 1:4 and no
significant difference in ratio or protein yield between any of the
oncogene-transfected or control cells. In addition to protein yields,
lamin and tubulin expression/distribution were used as both
loading controls and as a measure of quality of the fractionation
(figure 1b).
Comparative Analysis of the Effect of Expression of
Leukaemogenic Tyrosine Kinases on the Nuclear
Proteome
The number of proteins detected and relatively quantified with
high confidence in the 8 channels was 3619 with a false discovery
rate (FDR) of 4.6%. All the data was normalised such that the
median was 1.0 and the ratios checked to ensure they had
approximately a normal distribution (figure 1c). The total list of
proteins identified is shown in Table S1 with all relative
quantification values.
We next defined what constituted a change in protein expression.
To be called as changing a protein must have a ratio outside the
range in which 95% of protein ratios for the internal replicate are
found and a p-value of 0.05 or less in the majority of experiments
that a ratio is recorded and not changing in any internal replicate.
This ‘‘significance interval’’ was determined for each experimental
run and attempts to account for the technical and biological
variation seen in each run (see table S1). Protein changes were then
examined using a hierarchical clustering (figure 2a). The analysis
illustrated that there was very little similarity in the nuclear
proteome changes. There was no clustering of the oncogenes
involved in the myeloproliferative disorders and whilst FLT3ITD,
KIT D816V, Fip1L/PDGFRa (all type 3 leukaemogenic receptor
PTKs),didshowagreater,thoughverylimited,similaritycompared
with other oncogenes, TEL/PDGFRb, another type 3 receptor
PTK did not cluster with these structurally similar kinases in respect
of proteomic effects. Construction of an Edwards-Venn diagram
containing proteins with a change in expression between control
cells and each oncogene-transfected cell population also revealed
the lack of major overlap in effect between any of the oncogenes
(figure 2b). The few commonalities that were identified areshown in
table 1, but in general we conclude that leukaemogenic tyrosine
kinases have pleiotropic effects on nuclear protein expression.
Further informatic analysis did not identify a specific pathway that
was significantly affected by all 6 oncogenes via depletion or
enhancement of critical but distinct components. Phosphoproteo-
mic analysis also revealed significant differences in modes of action
between the oncogenicPTKsusing VennDiagramand hierarchical
clustering (Figures 2c and 2d and see section below). It is interesting
to note that the hierarchical clustering of the proteome changes and
phosphoproteome changes show different patterns. So for example
in the proteome changes NPM/ALK, FLT3ITD and KIT D816V
cluster together whereas in the phosphoproteome analysis KIT
D816V couples with Tel/PDGFbR. Of all the proteins identified,
294 were affected by expression of the NPM/ALK expression, 293,
105, 197 and 214 respectively by the myeloproliferative disorder
oncogenes BCR/ABL, TEL/PDGFRb, Kit D816V, and Fip1L/
PDGFRa respectively, and 194 in the FLT3 ITD oncogene found
in acute myeloid leukaemia (see table S3 for the list of proteins that
change as a consequence of oncogene expression).
Many of the Common Changes are Neither Due to
Protein Translocation nor mRNA Expression Changes
The lack of overall harmonisation in protein changes emanating
from the 6 PTKs led us to look at potential differential layers of
control in these systems. To determine whether transcription or
post-translational mechanisms were responsible for these changes
we compared the data on major protein changes we observed
against mRNA expression data we have previously published [14].
Protein Targets for Leukemogenic Tyrosine Kinases
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relationship between change in mRNA expression and proteome
change. Having used a nuclear preparation (required to generate
data on lower abundance proteins) the reason for this lack of
correlation between mRNA and protein change could be
translocation of proteins to or from the cytosol. We therefore
assessed PTK-induced changes in the cytosol using an equivalent
cytosol proteome database (AP, AW, ADW, ST unpublished
observations). The change in cytosolic and nuclear levels were
plotted (Figure 3b) for the proteins reported to be changing where
the proteins were present in both organelles. These data (Figure 3b)
clearly show that translocation of proteins was not responsible for
the majority of nuclear proteomic changes observed.
Given these data we determined if the involvement of any
specific transcription factor binding site on genes whose protein
levels change gave a strong correlation between protein changes
and mRNA changes. In other words do some transcription factors
drive an mRNA-mediated change in proteome more readily than
others? We analysed the transcription factor binding sites and the
most common included NFkB, Fos, Jun, PPAR-c and Glucocor-
ticoid receptor (GR). One outstanding observation from the
consideration of upstream transcription factor binding sites from
major changing proteins was the data seen with proteins changing
that have upstream glucocorticoid receptors (GRs) binding sites. In
no instance did increased protein expression with these gene
products correlate with increased mRNA expression (Figure 4a).
Where decreased protein expression was observed 38% of genes
displayed a .2fold decrease in mRNA levels (comparing control
and PTK transfected cells). This led us to examine the levels of GR
in PTK and control cells. Figure 4b shows the levels of GR present
in PTK expressing cells and their control, mock-transfected
counterparts. The GR protein decreased markedly when each
leukaemogenic PTK was expressed. Of course, GR was not found
in the proteome analysis as it requires activation for nuclear
localisation. Further evidence on the lack of activation came from
the use of a phospho GR antibody that recognises phosphorylation
on Serine 211 (Figure 4b): phospho Ser211 GR levels fell to a
greater degree than the levels of GR protein when oncogenic
PTKs were expressed. We also recorded that there was no
concomitant change in GR mRNA levels (Figure 4c). Thus
leukaemogenic PTKs regulate a fundamentally important signal/
response coupling pathway post-translationally. Given the use of
glucocorticoids to treat leukaemias via induction of apoptosis this is
a potentially significant finding. Re-instigation of GR responses
Figure 1. Work flow and quality control. Figure 1a displays a schematic representation of the experimental workflow. Nuclei were enriched from
control cells and those expressing the six oncogenes shown on three separate occasions. In each of the three biological replicates the control cells
were duplicated to produce an internal technical replicate. The nuclear lysates were then subject to the proteomic workflow illustrated. Figure 1b isa
representative western blot of one of the three biological replicate nuclear fractions. Following isolation 7.5 mg of nuclear and 30 mg of cytoplasmic
lysates were separated by SDS PAGE and the distribution of lamin and tubulin assessed by western blot analysis. Figure 1c and 1d, Distribution of
quantification ratios. These histograms show the distribution of (log) ratios for proteins (Figure 1c - proteome experiments) and phosphopeptides
(Figure 1d - phospho peptide experiments).
doi:10.1371/journal.pone.0038928.g001
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upstream pathways modulating GR protein expression is required.
NFkB1/2 binding sites were the most common transcription
factor binding site found on major changing proteins. This is of
interest because NFkB can modulate the GR response and vice
versa. IkB levels are a key determinant of NFkB complex
activation in cells and all the PTKs with the exception of BCR/
ABL decreased IkB (see Figure 5a,b). But a consideration of these
protein changes on genes with NFkB binding sites led to the
observation that there was no correlative modulation in mRNA
where significant protein changes are observed, except in the case
of BCR/ABL. With BCR/ABL a two fold modulation of mRNA
levels was observed in 50% of proteins whose levels changed in
response to expression of this kinase and where NFKB1/2 binding
sites are found in the promoter region. This was not the case with
any other PTK. As stated all the PTKs studied except BCR/ABL
decreased IkB levels, whilst BCR/ABL and KIT D816V increased
NFkB protein levels (Figure 5a). We also identified using
proteomics the HMGA1 protein which was up-regulated by the
oncogenic protein PTKs, this was confirmed by western blot
analysis (figure 5c). As a control we showed other HMG family
members were not changed as assessed either with mass
spectrometry or western blotting (Figure 5d). HMGA1 is an
enhancer protein for the NFkB transcription factor complex [15]
but with 5 of the 6 oncogenes under analysis this did not affect
NFkB regulated gene mRNA synthesis. Taken together these data
suggest pleiotropic effects of leukaemogenic PTKS pertain on the
NFkB pathway and whilst indicators of activation persist
(Figures 5a,b,c and decreased GR expression and activation
status) the concept of NFKB addiction in transformation [16] does
not apply when transformation is achieved directly and solely from
expression of leukaemogenic PTKs. GR level and activity status
reduction does not modulate oncogenic PTK-mediated NFkB
pathway activation. HMGA1 has multiple effector actions (such as
on DNA mismatch repair, see below) which may influence PTK
transformed cells with no recourse to NFkB signalling.
Comparative Analysis of the Effect of Expression of
Leukaemogenic Tyrosine Kinases on the Nuclear
Phosphoproteome
Approximately 25% of the proteins identified as changing in
response to five or six of the PTKs are linked to DNA repair
Figure 2. Analysis of potential oncogene relationships. Dendrogram analysis was performed using the standard heat map function of R.
Oncogenes are clustered according to similar protein expression profiles observed in iTRAQ ratios. Green indicates a decrease, red an increase and
black indicates no change in iTRAQ ratios. The dendrogram tree structure illustrates the relationship between the oncogenes. The varying length of
the horizontal ‘‘branch’’ indicates degree of similarity between the oncogenes-a shorter branch indicates a greater degree of similarity. Figure 2a is for
the nuclear proteome data and 2c the nuclear phosphoproteome data. An Edwards-Venn diagram was constructed to illustrate the protein changes
(figure 2b) and phosphopeptide changes (figure 2d) commonly caused by the oncogenes.
doi:10.1371/journal.pone.0038928.g002
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a major role in the development and progression of leukaemia [8].
The mechanisms in DNA repair revolve around serine/threonine
phosphorylation signalling events. Therefore, in addition to
investigating the nuclear proteome we investigated the nuclear
phosphoproteome. To achieve this following digestion of nuclear
proteins the resultant peptides were enriched on titanium dioxide
columns (figure 1a) prior to 2-dimensional LC and mass
spectrometry.
We identified a total of 1889 unique phosphoentities, giving
approximately 1558 distinct sites of phosphorylation on 705
different proteins (FDR of 0.32%). The amalgamated list is shown
in table S4 the total list with precursor mass and charge data in
table S5. As with the nuclear proteome analysis biological
replicates were employed to determine change in expression with
confidence (figure 1c and table S2). The phosphopeptide identified
from NF-IL3 illustrated the level of consistency that can be
obtained between proteome change and phosphopeptide change.
The phosphopeptide ratio compared to control in BCR/ABL,
NPM/ALK, FLT3 ITD and Fip1L/PDGFRa were 2.0, 1.8, 2.0
and 1.8 fold respectively. This compares with the data for the
protein which gives the following fold changes, 2.1, 1.7 1.8 and 1.9
in other words there was no change in the stoichiometry of
phosphorylation on this site.
Phosphopeptides whose expression was altered as a conse-
quence of oncogene expression are shown in table S6. The
lymphoma associated oncogene NPM/ALK significantly altered
the expression of 91phosphopeptides whilst the myeloproliferative
disorder oncogenes BCR/ABL, TEL/PDGFRb, Kit D816V, and
Fip1L/PDGFRa changed the expression of 94, 114, 111 and 68
respectively. In addition 72 phosphopeptides were altered by the
FLT3 ITD oncogene associated with acute myeloid leukaemia.
Phosphopeptide changes due to the PTKs were used to classify
PTK effects using hierarchical clustering (Figure 2c). As with the
nuclear proteome analysis there was very little similarity in PTK-
induced changes. Two receptor tyrosine kinases (TEL/PDGFRb
and Kit D816V) did group together though the effect was tenuous.
There was no significant pattern to the phosphorylated effectors
downstream of the 6 PTKs. This diversity in PTK-induced
changes is also illustrated in the Venn diagram shown in figure 2d.
A selection of the commonalities that were identified is shown in
Table 2. The above data demonstrate there are pleiotropic effects
of the PTKs on phosphorylation in the nucleus.
Identification of Common Downstream Nuclear Targets
for the Leukemogenic PTKs
Proteins previously associated with the development of leukae-
mias, such as hnRNP1 [17] and SHIP1 [18] the inositol lipid
phosphatase, show altered phosphorylation as a consequence of
the downstream action of several PTKs (table S6). A selection of
the phosphorylation events most commonly seen between the 6
PTK expressing cells are shown in Table 2. P53bp1 interacts with
the tumour suppressor protein p53 and has a role in DNA damage
response [19]. Its phosphorylation is affected by 4 of the PTKs in
the study but the oncogenes do not affect the expression level of
this protein. It has previously been reported that p53bp1 S1099 is
a phosphorylated downstream from Flt3 ITD [20]. We have now
demonstrated that in addition it is phosphorylated by several of the
PTKs studied here (namely BCR/ABL, NPM/ALK and TEL/
PDGFRb and Flt3 ITD). Decreased levels of Serine 211
phosphorylation on GR (Figure 4b) in response to leukaemogenic
PTK expression are far in excess of the decrease in protein levels
(in other words there is a decreased stoichiometry of phosphor-
ylation as well as a decreased GR protein level). This phosphor-
ylation is likely governed by serum supplement derived GR
agonists. The configuration of proteomic/mRNA changes ob-
served in our study led to this observation that can now be further
analysed for potential clinical relevance.
Similarities in changes in the protein level are shown in Table 1.
Cystatin C and bone marrow proteoglycan both change in
response to expression of all 6 PTKs. We have generated a nuclear
preparation free from cytosolic protein contamination and
extracellular medium which is illustrated by the lack of serum
proteins and key cytosolic proteins (see complete list in table S1
and figure 1b). Therefore one can infer these proteins are indeed
associated with nuclei. Given the role of cystatin C as a lysosomal
protein inhibitor there may be disregulation of lysosomal function
in PTK transformed cells potentially associated with disregulated
autophagy [21]. This is associated with inflammatory conditions, a
theme we extend below. Zinc Finger and BTB binding domain
protein 16 (ZBTB16) is a cell cycle regulatory transcription factor
[22] decreased in expression by 6 out of 6 PTKs in our study, this
protein associates with key regulators of hematopoiesis such as
GATA2, BMI1 and PML [23,24]. The protein showing the
greatest level of up-regulation was High Mobility Group Protein
A1 (or Y). Perhaps surprisingly TGFb is upregulated in four of the
six oncogene transfected cell lines. Elevation by leukaemogenic
PTKs is also seen in the cytosol (AP, ST, ADW, unpublished
observations). The importance of TGFb in the natural history of
CML is highlighted in a recent paper by Naka et al. [25] which
reported that inhibition of TGFb impaired colony formation in
CML and proposed a role for TGFb inhibition in CML treatment.
Given these important observations oncogenic PTK-transfected
and control cells were treated with the TGFb receptor kinase
inhibitor LY364947 and viability assayed over 3 days. No
differences in response were seen between PTK transfected and
control cell lines (figure S1).
NF-IL3 (E4bp4) is up-regulated by the action of 4 out of 6 PTKs
(Table 1) a target of IL-3 it plays an important role in survival;
indeed over-expression of NF-IL3 leads to IL-3 independence in
Ba/F3 cells [26]. This suggests that the oncogene-induced increase
in NFIL-3 expression may play a role in the oncogene expression
related growth factor independence seen in the Ba/F3 cells with
respect to BCR/ABL, NPM/ALK, FLT3 ITD and Fip1L/
PDGFRa.
PMS2 a DNA Mismatch Repair Protein is Down Regulated
by Leukaemogenic Protein Tyrosine Kinases
Another protein fundamentally linked to DNA repair and
markedly decreased (by .40% in the case of all PTKs except
Fip1L/PDGFRa (which gave a 28% though non-significant
reduction) was PMS2. We validated this observation by western
blot analysis (figure 6a). This demonstrated that all 6 leukaemo-
genic PTKs decreased PMS2 levels. Whether this was due to
Figure 3. Correlation between protein/mRNA and nuclear/cytosolic protein ratios for proteins identified as changing. Figure 3a;
Correlation of mRNA expression changes and protein expression changes for nuclear proteins in response to 6 leukaemogenic PTKs expressed as log2
fold changes. Figure3b; The nuclear and cytosolic changes in protein expression levels (expressed as a ratio value compared to control Ba/F3 cells
were plotted for the proteins in which a change of level was seen for four or more of the 6 leukaemogenic PTK transformed cells. Data are shown as
Log2 ratios with control mock transfected Ba/F3 cells as denominator.
doi:10.1371/journal.pone.0038928.g003
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based MS analysis of the cytosol proteome of the 6 leukaemogenic
PTK-transformed cells showed the presence of PMS2 but no
alteration in its levels (Figure 6b). Similarly mRNA levels for
PMS2 were not altered in a significant fashion. The observed
decrease in the nuclear PMS2 level is due then to mechanisms
other than transcriptional or protein shuttling mechanisms. To
confirm the specificity of this PMS2 effect another member of this
DNA mismatch repair complex (PCNA) was assessed by western
blot and shown to be unaffected or increased. A potential increase
of the protein level mediated by NPM/ALK and TEL/PDGFbR
was seen using iTRAQ (though this was below our threshold cut
off level) and by western blot, there was no correlation of any
change with mRNA changes (figure 6c,d).
DNA mismatch repair plays an important role in maintaining
genomic stability. Given our proteomic findings that pathways that
potentiate genomic stability are common targets mediated by 6
oncogenic PTKs we investigated whether such pathways were
perturbed in the oncogene expressing cells. Cells were treated with
the DNA mismatch repair inducing drug 6-thioguanine and
viability assessed 24 hours later. As is clearly illustrated in figure 6e
the oncogene expressing cells have a defect in their DNA repair
pathway showing a reduced viability following treatment. This
indicates that the oncogene expressing cells are less able than the
control cells to repair the DNA mismatches induced by the 6-
thioguanine.
The data on major protein changes and their interactions is
shown in Figure 7a. Furthermore, all protein changes have been
developed into a web-based system for checking proteins of
interest, depicted in Figure 7b.
Discussion
Our substantial analysis of the effects of 6 leukemogenic PTKs
has revealed a great deal of disparity in their effects in the nucleus,
a novel and important observation in itself. We then went onto
show that modulation of mRNA levels and nuclear/cytosolic
Figure 4. Glucocorticoid receptor changes in response to 6 leukaemogenic PTKs. Figure 4a; The correlation between mRNA level changes
and nuclear proteome changes for genes which display a GR binding region were plotted as log2 fold changes with control mock transfected cells as
the denominator. Figure 4b; Glucocorticoid Receptor protein levels and the degree of serine 211 phosphorylation of the glucocorticoid receptor in
response to expression of the 6 leukaemogenic PTKs were assessed by western blot. Figure 4c illustrates the mRNA expression level changes for the
glucocorticoid receptor in response to oncogenic PTK expression, none were statistically significant as measured by students T test.
doi:10.1371/journal.pone.0038928.g004
Figure 5. Western blot analysis of NFKb and HMGA1 pathways. Figure 5a to 5d; Cells were lysed or subject to nuclei fractionation before
assessment of protein expression by western blot analysis. Expression levels of the proteins shown were assessed in nuclear (figure 5a, 5c) or whole
cell lysates (figure 5b, 5d) and protein loading assessed by lamin A/C or actin expression.
doi:10.1371/journal.pone.0038928.g005
Protein Targets for Leukemogenic Tyrosine Kinases
PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e38928T
a
b
l
e
2
.
P
h
o
s
p
h
o
p
e
p
t
i
d
e
s
w
h
o
s
e
e
x
p
r
e
s
s
i
o
n
i
s
a
l
t
e
r
e
d
b
y
t
h
e
e
x
p
r
e
s
s
i
o
n
o
f
f
o
u
r
o
r
m
o
r
e
o
n
c
o
g
e
n
e
s
.
P
h
o
s
p
h
o
P
e
p
t
i
d
e
P
r
o
t
e
i
n
G
e
n
e
S
y
m
b
o
l
N
a
m
e
C
h
a
n
g
e
i
n
B
C
R
/
A
B
L
T
E
L
/
P
D
G
F
R
b
N
P
M
/
A
L
K
K
i
t
D
8
1
6
V
F
l
t
3
-
I
T
D
F
i
p
1
L
/
P
D
G
F
R
F
o
l
d
c
h
a
n
g
e
c
o
n
f
F
o
l
d
c
h
a
n
g
e
c
o
n
f
F
o
l
d
c
h
a
n
g
e
c
o
n
f
F
o
l
d
c
h
a
n
g
e
c
o
n
f
F
o
l
d
c
h
a
n
g
e
c
o
n
f
F
o
l
d
c
h
a
n
g
e
c
o
n
f
M
D
R
T
[
P
h
o
]
P
P
P
P
T
[
P
h
o
]
L
S
P
A
A
V
T
V
G
R
E
N
S
M
U
S
P
0
0
0
0
0
1
1
4
9
1
6
P
h
c
3
P
o
l
y
h
o
m
e
o
t
i
c
-
l
i
k
e
3
5
1
.
5
6
0
.
9
8
1
.
5
0
0
.
9
6
1
.
2
3
0
.
7
9
1
.
6
9
0
.
9
8
1
.
4
5
0
.
9
5
1
.
4
9
0
.
9
6
L
D
S
S
Q
L
P
L
Q
T
G
L
D
V
P
A
T
[
P
h
o
]
P
R
E
N
S
M
U
S
P
0
0
0
0
0
0
2
7
7
6
8
A
h
c
t
f
1
P
r
o
t
e
i
n
E
L
Y
S
(
P
r
o
t
e
i
n
M
E
L
-
2
8
)
5
1
.
5
0
0
.
9
6
1
.
2
0
0
.
7
4
1
.
4
4
0
.
9
5
1
.
6
0
0
.
9
8
1
.
4
7
0
.
9
6
1
.
5
7
0
.
9
8
D
S
Q
D
T
S
[
P
h
o
]
A
E
Q
S
D
H
D
D
E
V
A
S
L
A
S
A
S
G
G
F
G
S
K
E
N
S
M
U
S
P
0
0
0
0
0
0
3
9
1
3
4
E
d
c
4
E
n
h
a
n
c
e
r
o
f
m
R
N
A
-
d
e
c
a
p
p
i
n
g
p
r
o
t
e
i
n
4
4
0
.
4
2
0
.
9
9
0
.
9
5
0
.
2
8
0
.
5
8
0
.
9
8
1
.
0
4
0
.
1
8
0
.
3
8
0
.
9
9
0
.
5
5
0
.
9
9
G
P
I
H
S
[
P
h
o
]
P
V
E
L
Q
R
E
N
S
M
U
S
P
0
0
0
0
0
0
6
5
3
6
3
N
f
i
l
3
N
u
c
l
e
a
r
f
a
c
t
o
r
i
n
t
e
r
l
e
u
k
i
n
-
3
-
r
e
g
u
l
a
t
e
d
p
r
o
t
e
i
n
4
1
.
9
8
0
.
9
6
1
.
2
7
0
.
7
5
1
.
7
5
0
.
9
4
1
.
3
4
0
.
7
5
2
.
0
3
0
.
9
6
1
.
8
4
0
.
9
6
Q
S
E
Q
P
V
K
P
V
G
P
V
M
D
D
A
A
P
E
D
S
A
S
P
V
S
[
P
h
o
]
Q
Q
R
E
N
S
M
U
S
P
0
0
0
0
0
1
0
6
2
7
5
T
r
p
5
3
b
p
1
T
u
m
o
r
s
u
p
p
r
e
s
s
o
r
p
5
3
-
b
i
n
d
i
n
g
p
r
o
t
e
i
n
1
4
1
.
9
0
0
.
9
9
1
.
4
7
0
.
9
6
1
.
6
6
0
.
9
8
1
.
4
1
0
.
9
4
1
.
4
8
0
.
9
6
1
.
3
1
0
.
8
7
L
Q
P
L
T
S
V
D
S
[
P
h
o
]
D
N
D
F
V
T
P
K
E
N
S
M
U
S
P
0
0
0
0
0
1
0
7
9
1
0
N
c
a
p
d
2
C
o
n
d
e
n
s
i
n
c
o
m
p
l
e
x
s
u
b
u
n
i
t
1
4
2
.
0
2
0
.
9
9
1
.
9
0
0
.
9
9
1
.
5
4
0
.
9
8
2
.
0
7
0
.
9
9
1
.
1
7
0
.
6
9
0
.
9
3
0
.
3
6
E
L
L
L
D
I
G
D
V
S
[
P
h
o
]
E
R
E
N
S
M
U
S
P
0
0
0
0
0
0
2
6
4
4
8
A
2
A
C
J
2
F
a
n
c
o
n
i
a
n
e
m
i
a
-
a
s
s
o
c
i
a
t
e
d
p
r
o
t
e
i
n
4
0
.
4
9
0
.
9
9
0
.
4
5
0
.
9
9
0
.
7
6
0
.
8
8
0
.
5
3
0
.
9
9
0
.
6
0
0
.
9
8
0
.
7
5
0
.
8
9
S
[
P
h
o
]
P
L
D
N
M
S
R
E
N
S
M
U
S
P
0
0
0
0
0
0
7
9
8
1
8
E
t
v
6
E
t
s
v
a
r
i
a
n
t
g
e
n
e
6
(
T
E
L
o
n
c
o
g
e
n
e
)
4
1
.
3
4
0
.
8
9
1
.
5
2
0
.
9
7
1
.
7
7
0
.
9
9
1
.
8
0
0
.
9
9
1
.
5
6
0
.
9
8
1
.
3
4
0
.
8
9
P
h
o
s
p
h
o
p
e
p
t
i
d
e
s
s
h
o
w
n
a
r
e
a
s
e
l
e
c
t
i
o
n
w
h
e
r
e
a
c
o
n
f
i
d
e
n
t
a
s
s
e
s
s
m
e
n
t
o
f
a
c
o
m
m
o
n
d
e
c
r
e
a
s
e
o
r
i
n
c
r
e
a
s
e
i
n
4
o
r
m
o
r
e
o
f
t
h
e
6
o
n
c
o
g
e
n
e
s
h
a
s
b
e
e
n
f
o
u
n
d
.
T
o
b
e
i
n
c
l
u
d
e
d
t
h
e
p
e
p
t
i
d
e
m
u
s
t
b
e
c
a
l
l
e
d
a
s
c
h
a
n
g
i
n
g
i
n
t
h
e
m
a
j
o
r
i
t
y
o
f
e
x
p
e
r
i
m
e
n
t
s
i
n
w
h
i
c
h
i
t
i
s
q
u
a
n
t
i
f
i
e
d
a
n
d
m
u
s
t
n
o
t
b
e
c
a
l
l
e
d
a
s
c
h
a
n
g
i
n
g
i
n
t
h
e
i
n
t
e
r
n
a
l
r
e
p
l
i
c
a
t
e
.
T
o
b
e
c
a
l
l
e
d
a
s
c
h
a
n
g
i
n
g
a
p
e
p
t
i
d
e
m
u
s
t
h
a
v
e
a
r
a
t
i
o
o
u
t
s
i
d
e
t
h
e
r
a
n
g
e
o
f
w
h
i
c
h
9
5
%
o
f
p
h
o
s
p
h
o
p
e
p
t
i
d
e
r
a
t
i
o
s
f
o
r
t
h
e
i
n
t
e
r
n
a
l
r
e
p
l
i
c
a
t
e
a
r
e
f
o
u
n
d
.
T
h
e
r
a
t
i
o
c
o
l
u
m
n
c
o
n
t
a
i
n
s
a
n
a
v
e
r
a
g
e
o
f
t
h
e
r
a
t
i
o
s
a
c
r
o
s
s
m
u
l
t
i
p
l
e
e
x
p
e
r
i
m
e
n
t
s
.
T
h
i
s
i
s
s
u
p
p
o
r
t
e
d
b
y
t
h
e
a
v
e
r
a
g
e
d
c
o
n
f
i
d
e
n
c
e
w
h
i
c
h
i
n
d
i
c
a
t
e
s
h
o
w
c
l
o
s
e
l
y
t
h
e
e
x
p
e
r
i
m
e
n
t
s
a
g
r
e
e
.
T
h
e
c
o
n
f
i
d
e
n
c
e
f
o
r
e
a
c
h
e
x
p
e
r
i
m
e
n
t
i
s
t
h
e
p
r
o
p
o
r
t
i
o
n
o
f
r
a
t
i
o
s
i
n
t
h
e
i
n
t
e
r
n
a
l
r
e
p
l
i
c
a
t
e
t
h
a
t
t
h
e
r
a
t
i
o
i
n
q
u
e
s
t
i
o
n
i
s
o
u
t
s
i
d
e
o
f
.
(
S
o
t
h
e
v
a
l
u
e
f
o
r
a
n
‘
U
p
’
c
a
l
l
i
s
b
e
t
w
e
e
n
0
.
9
5
a
n
d
0
.
9
9
i
n
c
l
u
s
i
v
e
)
.
T
h
i
s
g
i
v
e
s
a
n
o
r
m
a
l
i
s
e
d
v
a
l
u
e
b
e
t
w
e
e
n
2
0
.
9
9
a
n
d
0
.
9
9
f
o
r
e
a
c
h
e
x
p
e
r
i
m
e
n
t
.
A
v
a
l
u
e
o
f
g
r
e
a
t
e
r
m
a
g
n
i
t
u
d
e
i
n
d
i
c
a
t
e
s
m
o
r
e
a
g
r
e
e
m
e
n
t
b
e
t
w
e
e
n
e
x
p
e
r
i
m
e
n
t
s
s
u
p
p
o
r
t
i
n
g
t
h
e
c
h
a
n
g
e
c
a
l
l
.
V
a
l
u
e
s
n
o
t
i
n
b
o
l
d
a
r
e
t
h
o
s
e
n
o
t
c
a
l
l
e
d
a
s
c
h
a
n
g
i
n
g
(
d
e
t
a
i
l
s
c
a
n
b
e
f
o
u
n
d
i
n
t
h
e
s
u
p
p
o
r
t
i
n
g
i
n
f
o
r
m
a
t
i
o
n
t
a
b
l
e
s
)
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
3
8
9
2
8
.
t
0
0
2
Protein Targets for Leukemogenic Tyrosine Kinases
PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e38928Figure 6. Regulation of the expression of DNA mismatch repair protein PMS2. Figure 6a; PMS2 expression levels were assessed by western
blot analysis in whole cell lysates and actin expression used as a loading control. Figure 6b shows the Isobaric tagging tandem MS relative
quantification data for PMS2 levels in the nucleus and cytosol and comparison of these values to mRNA changes observed for PMS2. Figure 6c; PCNA
expression levels were assessed by western blot analysis in whole cell lysates. Actin expression was used as a loading control. Figure 6d; isobaric
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PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e38928shuttling were not responsible for the major changes seen in the
nuclear proteome instigated by the leukaemogenic PTKs. The
very fact that translocation and mRNA modulation do not
account for many of the changes observed underlines the need for
organellar proteomic analyses to identify the targets downstream
of oncogenic PTKs and also the need for further research on
mRNA processing and translation regulation plus protein hydro-
lysis mediated by leukaemogenic PTKs.
A key example of a changing protein is HMGA1. This protein
has been shown to be relevant in the leukaemias showing increased
expression in a major proportion of Acute Myeloid Leukaemia
cases [27]. This non-histone protein is highly expressed during
embryogenesis and involved in many cellular processes, including
regulation of gene transcription and potentially DNA damage via
its interaction with BRCA1 [28]. Its role in transformation has
been documented extensively elsewhere: HMGA1 is elevated in
poorly differentiated carcinomas where its expression is related to
a poor prognosis; HMGA1 induces oncogenic transformation in
cultured cells and causes lymphomas in transgenic mice (for a
review see [29]). Also cells over-expressing HMGA1 exhibit
increased UV sensitivity due to effects on inhibition of nucleotide
excision repair. XPC protein, a component of the nucleotide
excision repair pathway involved in correction of G/T mismatches
[30]. Western blot analysis confirms the iTRAQ data (figure 4d)
that HMGA1 specifically amongst HMG family members is up-
regulated by all the six oncogenes. In our experiments we have
shown HMGA1 elevation is not associated with increased NFkB
responsive gene expression despite its role as an enhancer for the
NFkB complex.
Other interactors of HMGA1may therefore also be important.
HMGA1 can modulate the response to insulin and to interact with
the key hematopoietic regulator C/EBPb [31]. Elevated expres-
sion of cytokines like IL-3 and Kit ligand are a part of the
pathogenesis of diseases such as Chronic Myeloid Leukaemia, the
proven ability of increased HMGA1 expression to bind the Kit
ligand promoter and enhance expression thereof adds another
facet to the pleiotropic effects of elevated HMGA1 expression
[32].
As described above, GR gene targets are potentiated by the 6
PTKs and the levels of this key receptor are decreased markedly
by 6 out of 6 of the leukaemogenic PTKs. Phosphorylation on a
GR site associated with activation [33] is also decreased. The GR
agonists have been implicated in regulation of erythropoiesis [34]
and are required for optimal maintenance of hematopoietic
primitive cells in long term marrow cultures [35]. Glucocorticoids
are employed to great effect in the treatment of some leukaemias
[36,37]. Thus the observation that leukaemogenic PTKs decrease
expression levels of GR has potential clinical implications.
Acquired steroid resistance is a serious clinical issue [38,39,40]
that can affect outcome. Acquired mutations may be responsible
for this and now we have some indication that signal transduction
pathway activation can underlie this. In our model system we can
investigate upstream events that account for the observed GR
down-modulation. In so doing we can identify potential thera-
peutic strategies to instigate a response to steroid treatment that
could lead to leukaemic cell apoptosis.
A study on the occurrence of mutations in two proteins involved
in DNA mismatch repair, MSH2 and MLH1, has previously
implicated alterations in this pathway in AML pathogenesis [41].
Here we demonstrate that PMS2, another protein involved in
DNA mismatch repair is altered by oncogene expression. PMS2
has previously been reported to be associated with Lynch
Syndrome [42] and colorectal cancer [43]. PMS2 recessive
mutations have been associated with leukaemias [44]. It is a
downstream target of p53 and is believed to sense DNA damage
enabling decisions on repair versus commitment to apoptosis [45].
We reasoned that the reduced levels observed in the wake of
expressing oncogenic PTKs would likely alter the balance between
survival and apoptosis in PTK expressing cells. This indeed was
the case as oncogene-transfected cells subjected to 6-thioguanine
treatment, a drug which induces DNA mismatches, were less able
to survive compared to their normal counterparts. Decreased
response to drug is seen where PMS2 deletion occurs and in this
context the results we observe could be said to be counterintuitive.
However other data from PMS2 heterozygotic animals show this is
not the case. It is clear that PMS2 null mice, and specifically rates
of mutation therein, are dramatically different with PMS2+/2
mice [46]. In the effects of the 6 oncogenic PTKs we see
approximately 50% reduction in PMS2. This will not necessarily
generate the lack of response seen in PMS2 null human disease
and mouse models [44,47]. Rather the subtle but still statistically
significant effect we observe in response to thioguanine in the
presence of the leukaemogenic PTKs is more in keeping with the
literature on PMS2 heterozygosity [46]. Thus our endeavour to
identify mechanisms of control for the nuclear proteome and
triangulate a common nuclear effect of 6 oncogenic PTKs from
lymphoma, AML and MPDs has yielded a target that may be of
benefit in the clinic. This PMS2 observation could not have been
made with mRNA measurements demonstrating the need for
proteomics-based discovery. Furthermore, there is a differential
response to thioguanine and as such the use of drugs such as
PolyADP Ribose Polymerase in combination with chemothera-
peutic agents that invoke DNA mismatch repair may increase
leukaemic cell kill.
Protein phosphorylation effectors of the oncogenic PTKs is
likely in part explained by their differential subcellular localization
as well as pathways activated in the cell. Choudhary et al [20]
show that Flt3-ITD expressed in different parts of the cell affects
different signalling pathway activation. They also demonstrate that
there is a common effector pathway between the different Flt3ITD
species examined. This group also note the phosphorylation of
Polyhomeotic homolog 3 by Flt3ITD, this is a target found in our
studies (affected by 5/6 PTKs) that modifies chromatin via
monoubiquitination of histone H2A. Clearly the oncogenic PTKs
studied promote further rounds of post-translational modifications.
ELYS is also a major downstream target of the oncogenic PTKs
(Table 2), a protein involved in chromosome/nuclear pore
complex machinery that has a role in mitosis, post-translational
regulation may promote inappropriate events during cell division.
Fanconi Anemia associated Protein phosphorylation is down
modulated by leukaemogenic PTKs, this protein can regulate
Fanconi protein repair complex specifically via FANCD2
ubiquitination [48]. P53 Binding Protein 1 shows increased
phosphorylation in the PTK-transfected cells, this post-transla-
tional modification is also associated with DNA damage [49].
Thus there is potentiation of DNA damage repair pathways on a
number of levels.
tagging tandem MS relative quantification of nuclear PCNA levels and comparison of these values to mRNA values for PMS2. Figure 6e; Control and
leukaemogenic PTKs transfected Ba/F3 cells were cultured with mIL-3 in the presence or absence of 6-thioguanine (3 mM) for 24 hours and viability
assessed by trypan exclusion. The results of a t-test between treated and untreated are shown and represented by; * ,0.01, ** ,0.005, *** ,0.001.
doi:10.1371/journal.pone.0038928.g006
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PLoS ONE | www.plosone.org 15 June 2012 | Volume 7 | Issue 6 | e38928Our results are summarised in figure 7a in respect of pathway
analysis of effects observed. We conclude that our study, by taking
cell cycle status out of the equation, assessing protein translocation
to the cytosol and mRNA changes for key nuclear protein changes
has highlighted post-translational control as key in leukaemogenic
PTK action and identified several targets that are common for
these PTKs. This idea of post translational control was recently
highlighted in a study of protein tyrosine phosphatases (PTP)
activity in normal and oncogenic signalling [50]. Kariash et al
were able to demonstrate that cancer cells display distinctive
patterns of PTP activity revealing additional levels of complexity in
the regulation of protein-tyrosine phosphorylation in normal and
malignant cells. In addition they were able to demonstrate
regulation of phosphatase activity via ROS which could link this
phenomenon through to leukaemic oncogenic PTKs which are
known to increase ROS [51]. These data offer reasons for the
complexity seen in the effects of the 6 oncogenic kinases we have
studies. However the approach we have employed offers only a
picture of the equilibrium phosphopeptide status and further work
will be required to identify if this is modulated by protein kinase
activity change or protein phosphatase activity change. The
repository provided from our screen will be of value to those
studying a number of distinct leukaemias and is accessible through
user friendly software (Figure 7b) http://www.scalpl.org/scope3/.
Further validation studies will identify potential targets for therapy
in PTK-mediated malignant disease.
Materials and Methods
Cell Lines
Ba/F3 cells [52] were transfected with either an ‘‘empty’’
MSCV retroviral vector, or MSCV containing BCR/ABL, TEL/
PDGFRb, Fip1L/PDGFRa, KIT D816V, NPM/ALK or
FLT3ITD and maintained as stable cell lines as previously
described. [14] The resultant cell lines were maintained in culture
in Fischer’s medium (Invitrogen, Paisley, UK) with 10% (v/v)
horse serum (Biowest, Nuaille ´, France). Ba/F3-MSCV cells were
grown in Fischer’s medium with 10% (v/v) horse serum
supplemented with 5% (v/v) mIL-3 (conditioned media from
X63-Ag-653 cells).
Preparation of Cellular Nuclei and Western Blot Analysis
Nuclear proteins were enriched using a kit from Active Motif
(Rixensart, Belgium) with some modifications. Briefly, 1610
7 cells
were washed in ice cold Hanks buffer with protein phosphatase
inhibitors and incubated in hypotonic buffer (750 ml) as per
manufacturer’s instructions. The preparation was then incubated
on ice for 20 minutes in 50 ml TEAB (0.5 M), 0.05% (w/v) SDS
and 0.5 ml of protease inhibitor cocktail (Active Motif) and 2 ml/ml
Benzonase (Novagen, UK). The preparations were mixed,
centrifuged for 10minutes at 14,000 g and the supernatant
(nuclear fraction) recovered. The quality of the preparations was
confirmed using western blot analysis for nuclear (lamin A/C) and
cytosolic (a tubulin) standard marker proteins.
Whole cell lysates were prepared by lysing cells in RIPA buffer
(50 mM Tris pH 7.4, 1% NP-40, 0.25% Na-deoxycholate,
150 mM NaCl and 1 mM EDTA). Briefly cells were washed
three times with Phosphate buffered saline before lysing in RIPA
buffer with the following additions; Protease Inhibitor Cocktail
(Sigma-Aldrich, cat. #P8340), Phosphatase Inhibitor Cocktail 2
and 3 (Sigma-Aldrich, cat #P5726 and #P0044) and sodium
orthovanadate (1 mM). Western blot analysis was carried out by
standard protocols. Antibodies used were actin (A5060), HMGA1
(SAB2501305) from Sigma (Poole, UK); a tubulin (sc-5286), NFkB
(sc-372), IkB (sc-371) and Glucocorticoid receptor (sc-1004) from
Santa Cruz (Wembley, UK); Lamin A/C (# 2032) Phospho
Ser211 Glucocorticoid Receptor (#4161) from Cell Signalling
Technology (Hitchin, UK); HMGb1 (ab18256), HMGb2
(ab11973), HMG14 (ab5212) from Abcam (Cambridge, UK);
GSK3 phospho Y216 (612312), PCNA (610664) and PMS2
(556415) from Becton Dickenson (Oxford, UK); HSP90b (RB-
118-PO) from Thermo Scientific (Runcorn, UK); GSKa/b
(KAM-SToo2) from Enzo Life Sciences (Exeter UK).
Work Flow
The work flow is outlined in figure 1. Nuclei were enriched from
control cells (MSCV) and those expressing the six oncogenes on
three separate occasions to provide three biological replicates. In
each of these three biological replicates the control cells were
duplicated to produce an internal replicate.100 mg of nuclear
proteins from each cell line were reduced, alkylated and subject to
tryptic digestion prior to labelling with 8 channel isobaric tagging
ITRAQ
TM reagent in 1 M TEAB, according to the manufactur-
er’s instructions (in all experiments isobaric labelling exceeded
98% of total identified peptides using mass spectrometry, see
below). Isobarically tagged peptides were then taken forward for
analysis or subject to phosphopeptide enrichment on TiO2
columns. The ensuing nanoflow liquid chromatography plus
tandem mass spectrometry were performed as described previ-
ously [14] and are in further detailbelow. Mass spectrometry data
were processed using Protein Pilot software 3 (ABSciex, USA).
The experiment (including generation of cell pellets) was
performed three times for both proteome and phosphopeptide
assessment. A change in protein level is defined as a ratio where
the p-value is not more than 0.05 and the ratio is outside of 95% of
all ratios for the internal replicate. A change in phosphopeptide
level is defined as a ratio that is outside of 95% of all ratios for the
internal replicate. The ratios for these confidence ‘intervals’ for all
the experiments are shown in table S2.
TiO2 Mediated Enrichment of Phosphopeptides
100 mg of nuclear iTRAQ labelled peptide mixtures were re-
suspended in 150 ml of lactate loading buffer (240 mg/mL
lactate in 80% (v/v) acetonitrile, 1% (v/v) Trifluoro-acetic acid
(TFA). TiO2 columns (TopTip, Glygen Corp, USA) were
equilibrated with 150 ml of lactate loading buffer then the
samples loaded. The tip was washed twice with 60 ml of lactate
loading buffer and four times with 60 ml of wash buffer (80% (v/
v) acetonitrile, 5% (v/v) TFA). Bound peptides were then
recovered by elution in 60 ml of elution buffer (ammonium water
[20 mlN H 3 in 980 ul H2O], pH 10.5). Samples were then
concentrated to a few ml in a SpeedVac prior to RP-LC-MS/
MS as above.
Figure 7. Schematic analyses of proteomic data. Figure 7a: Ingenuity pathway analysis software was used to examine the HMGA1 interaction
network within the differentially regulated proteins/phospho-peptides regulated by oncogenic PTKs found in the study. Immediate interactors that
are differentially regulated in at least two oncogenes are shown while further interaction relationships are shown where differential regulation is
indicated in three or more oncogenes. The mini-heatmaps show the regulation seen in the six oncogenes. Red indicates up-regulation and green
down-regulation. From left to right the six columns show BCR/ABL, TEL/PDGFRb, NPM/ALK, Kit D816V, Flt3-ITD and Fip1L/PDGFRa. Figure 7b; A
screen snap of the interactive web-based viewer used to display the data. The web site can be found at http://www.scalpl.org/scope3/.
doi:10.1371/journal.pone.0038928.g007
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Prior to reversed phase LC-MS/MS peptides were fractionated
off line using a reversed phase chromatography column (Fortis
technologies, C18 3 mm 100/4.6 Reversed phase column) at a
high pH using an LC Packings Ultimate LC system. The gradient
was run at 700 ml/min using initially 99.5% high pH buffer A
(0.1% Ammonium hydroxide, adjusted to pH 10.5 with formic
acid) 0.5% high pH buffer B (0.1% Ammonium hydroxide, 99.9%
acetonitrile). Over a 30 minute time period high pH buffer B was
increased to 50%, followed by a 4 minute time period to increase
high pH buffer B to 75%. The concentration of high pH buffer B
(75%) was held for 4 minutes then reduced back down to 0.5%.
Fifteen second fractions were collected for the duration of the
gradient, the volume of each fraction was then decreased under
vacuum.
Mass Spectrometry
Peptides were identified by RP-LC-MS/MS on either a QStarH
XL, QStarH Elite or Tof/Tof 5800 mass spectrometer (AB Sciex,
UK). For the QStarH XL dried peptide fractions were re-
suspended in 180 ml of 2% (v/v) acetonitrile/0.1% (v/v) formic
acid. For each analysis one third of the peptide sample was loaded
onto a 15 cm reversed phase C18 column (75 mm inner diameter)
packed with C18 PepMap100 (3 mm, 100 A ˚) using an LC Packings
(Amsterdam, Netherlands) UltiMate
TM pump and separated as
described previously (R.D.Unwin et al. Molecular Cellular
Proteomics. 2005, 4, pp924–935). Briefly, peptides were separated
over a 120 min solvent gradient from 5.9% (v/v) acetonitrile/
0.1% (v/v) formic acid to 41% (v/v) acetonitrile/0.1% (v/v)
formic acid on-line to a QStarH XL mass spectrometer (AB Sciex,
UK). Data was acquired using an information dependant
acquisition (IDA) protocol where, for each cycle, the two most
abundant multiply charged peptides (2
+ to 4
+) above a 20 count
threshold in the MS scan with m/z between 400 and 2000 were
selected for MS/MS. Each peptide was dynamically excluded
(650 mmu) for 1 minute.
For the QStarH Elite dried peptide fractions were re-suspended
in 15 ml of 3% (v/v) acetonitrile, 0.1% (v/v) formic acid and
20 mM citric acid. For each analysis, 5 ml of the peptide sample
was loaded onto a nanoACQUITY UPLC Symmetry C18 Trap,
5 mm, 180 mm620 mm and flow was set to 15 ml/min of 3% (v/v)
acetonitrile, 0.1% (v/v) formic acid and 20 mM citric acid for
5 min. Analytical separation of the peptides was performed using
nanoACQUITY UPLC BEH C18 Column, 1.7 mm,
75 mm6250 mm. Briefly, peptides were separated over a 91 min
solvent gradient from 3% (v/v) acetonitrile,0.1% (v/v) formic acid
20 mM citric acid to 40% (v/v) acetonitrile,0.1% (v/v) formic
acid, 20 mM citric acid on-line to a QStarH Elite mass
spectrometer (AB Sciex, UK). Data was acquired using an
information dependant acquisition (IDA) protocol where, for each
cycle, the four most abundant multiply charged peptides (2
+ to 4
+)
above a 10 count threshold in the MS scan with m/z between 400
and 2000. Each peptide was dynamically excluded (650 mmu) for
90 seconds.
For the Tof/Tof 5800 system dried peptide fractions were re-
suspended in 180 ml of 2% (v/v) acetonitrile/0.1% (v/v) formic
acid and a third of the sample loaded onto a trap column using a
U3000 liquid chromatography system (Dionex, Sunnyvale, CA)
and the peptides fractionated by a capillary RP C18 HPLC
column (Acclaim PepMap C18, 3 mM1 0 0 A ˚) at a flow rate of
0.8 ml/min with a gradient of between 2–40% (v/v) acetonitrile,
0.1% (v/v) TFA over 80 minutes. The flow through was spotted
onto a MALDI plate (AB SCIEX, UK) in 15 second fractions
using an online Probot (Dionex, Sunnyvale, CA) with a-cyano-4-
hydroxycinnamic acid mixing with the eluant to a final
concentration of 1.25 mg/ml. Mass spectrometry was carried
out on an AB SCIEX TOF/TOF 5800 (AB SCIEX, Framing-
ham, USA) using 1000 shots for MS. MS/MS was carried out on
the top 27 precursors with a S/N of higher then 8 using 4000
laser shots, a 2 Kv acceleration voltage and air as the collision
gas.
Data Analysis
Data was processed by a ‘Thorough’ search against the ensembl
(FIXME reference www.ensembl.org) mouse database (release 58)
containing 115,658 protein entries using ProteinPilot 3 software
(Paragon version 3.0.0.0, 113442) with default settings including
the allowance of one missed or nonspecific cleavage (AB SCIEX,
Framingham, USA), MMTS and 8 plex iTRAQ fixed modifica-
tions. For a list of all variable modifications see ProteinPilot 3.
Phosphopeptides identified with a confidence of .20 were
included in the analysis. ProteinPilot quantification was used for
the proteome experiments. For the phosphopeptide experiments,
inferred phosphopeptide entities were selected from the Protein-
Pilot search results. The calculation used by ProteinPilot to derive
a weighted average ratio for proteins was used to derive an average
ratio where multiple spectra were found for a given distinct
phosphoentity (that is, a distinct sequence and set of modified
amino acids). As the number of identifications for an entity is
usually very low the p-value was calculated where possible but not
used to determine a change.
Microarray Analysis
RNA was prepared using TRIzol (Invitrogen), DNase treated
then cleaned using MinElute RNeasy Clean up Kit (Qiagen) per
manufacturers instructions. Transcriptome analysis was undertak-
en using murine GeneChipH Mouse Exon 1.0 ST Arrays by the
CR-UK Affymetrix microarray facility (Paterson Institute, Man-
chester, UK; http://bioinformatics.picr.man.ac.uk/vice/
Protocols.vice). All data were analysed as previously reported [14].
Interactive Web-based Viewer of Data
An interactive web-based viewer for the data is available at
http://www.scalpl.org/scope3/. A screen snap of the display is
shown in figure 7b. This tool gives a clustered view of all proteins
or phosphopeptides that were discovered (each represented by a
hexagon). The clustering was performed using the GATE software
[53]. The brightness of each hexagon indicates the significance of
change determined for the protein or phosphopeptide and selected
oncogene (red for up-regulation and green for down-regulation).
The oncogene to which the comparison is made can be changed
from the menu above the hexagon display. By hovering the
pointer over a hexagon the effects of the different oncogenes can
be quickly compared using the bar chart on the right side of the
display. Further information from gene ontology and the change
‘calls’ can be overlaid on the display by selecting them from the list
below the bar chart. Clicking on a hexagon displays more detailed
information for that protein in the panel below.
Supporting Information
Figure S1 TGFb inhibitor studies. Control and leukaemo-
genic PTKs transfected Ba/F3 cells were cultured in the presence
of 0, 0.5, 1.0, 5.0, 10 and 50 mM of the TGFb receptor inhibitor
LY364947 (Calbiochem, UK). Cell viability was assessed at 24, 48
and 72 hours by trypan blue exclusion.
(PDF)
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nuclear proteins identified across the three replicate experiments
of Ba/F3 cells transfected with 6 oncogenic PTKs. The first four
columns display protein and gene accessions, gene symbol and
name. The next nine columns give information from the search
results for the identification of the protein in each experiment
(blanks if not identified). ‘‘Coverage’’ indicates what percentage of
the protein sequence was identified. ‘‘Unique peptides’’ indicates
the number of unique peptides discovered whilst ‘‘Peptides used’’
indicates the number of unique peptides used to derive the
quantification. The remaining columns give, for each oncogene in
turn, quantification ratios (against MSCV control) and associated
p-values and error factors for each replicate.
(XLSX)
Table S2 Change significance interval. Table showing the
ratios employed to define a change. These are the values that 95%
of ratios for the internal replicate lie between. This ‘‘significance
interval’’ is individually determined for each experimental run and
attempts to account for the technical and biological variation seen
in each run.
(DOCX)
Table S3 Proteins changing as a result of expression of
each oncogene. Proteins defined as changing are shown for each
oncogene separately. To be called as changing a protein must have
a ratio outside the range in which 95% of protein ratios for the
internal replicate are found and a p-value of 0.05 or less in the
majority of experiments that a ratio is recorded and not changing
in any internal replicate. The first four columns display protein
and gene accessions, gene symbol and name. The ‘‘change’’
column gives a significance for the likelihood of all the ratios
representing a change and whether this is an increase or decrease
in protein expression. The next three columns indicate in how
many replicates the observation was made and whether it was an
increase or decrease. ‘‘Coverage’’ indicates the percentage of the
protein sequence identified. ‘‘Unique peptides’’ indicates the
number of unique peptides discovered whilst ‘‘Peptides used’’
indicates the number of unique peptides used to derive the
quantification. The remaining columns give, for each oncogene in
turn, quantification ratios (against MSCV control) and associated
p-values and error factors for each replicate.
(XLSX)
Table S4 All phosphopeptides identified. Table showing
all phospho peptides identified across the three replicate
experiments. The first four columns give protein and gene
accessions, gene symbol and name from which each peptide
originates. The next two columns list the modification assigned to
each peptide and the peptide sequence. The next six columns
display a value for the confidence with which the peptide was
matched (Confidence) and the number of matches used for the
quantification (Observations Used) for each of the three replicate
runs. The remaining columns give, for each oncogene in turn,
quantification ratios (against MSCV control) and associated p-
values and error factors for each replicate.
(XLSX)
Table S5 Phosphopeptide spectra. Table showing all
phospho peptides identified across the three replicate experiments
and their observed mass and charge. The first column shows
which experiment the peptide was seen. The next two columns
display a unique number identifying the spectrum and the peptide
match to the spectrum. The next three provide the accession
number, peptide sequence and cleavage information. The next
columns display a value for the confidence with which the peptide
was matched (Confidence). The next four columns provide
information on the charge, precursor mass and whether the
peptide was used in the quantification calculation and an
explanation as to why it was excluded if not used in the
quantification.
(XLSX)
Table S6 Phosphopeptides changing as a result of
expression of each oncogene. Phosphopeptides defined as
changing are shown for each oncogene. To be called as changing a
peptide must have a ratio outside the range in which 95% of
peptide ratios for the internal replicate are found in at least one
experiments and not changing in any internal replicate. The first
four columns give phosphopeptide sequence, protein accession,
gene symbol and name from which each peptide originates. The
‘‘change’’ column gives a significance for the likelihood of all the
ratios representing a change and whether this is an increase or
decrease in peptide expression. The next three columns indicate in
how many replicates the observation was made and whether it was
an increase or decrease. The remaining columns then display for
each replicate a value for the confidence with which the peptide
was matched (Confidence), the number of matches used for the
quantification (Spectra Used), a value for the confidence in the
likelihood of all the ratios representing a change (Change) and
quantification ratios (against MSCV control) and associated p-
values and error factors.
(XLSX)
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